AKT 10081

Drug Profile

AKT 10081

Alternative Names: AKT-10081

Latest Information Update: 17 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Akthelia Pharmaceuticals
  • Class Antidiarrhoeals; Peptide antibiotics; Peptides
  • Mechanism of Action Peptide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Clostridium infections; Diarrhoea

Most Recent Events

  • 17 Jan 2018 Phase-II development in Clostridium infections is ongoing in Iceland (Akthelia Pharmaceuticals pipeline, January 2018)
  • 17 Jan 2018 Phase-II development in Diarrhoea is ongoing in Iceland (Akthelia Pharmaceuticals pipeline, January 2018)
  • 18 Dec 2015 AKT 10081 is available for licensing as of 18 Dec 2015. http://www.akthelia.is/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top